Eli Lilly and Co. (NYSE:LLY) shares were little changed in Monday’s premarket session.

The U.S. drug giant shared results from the Phase 3 BRUIN CLL-322 trial of Jaypirca (pirtobrutinib), which showed significant improvement in progression-free survival when combined with venetoclax and rituximab.

The trial included patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).

CLL/SLL is a type of blood cancer. Specifically, it is a cancer of a type of white blood cell called the B-lymphocyte.

AbbVie Inc. (NYSE:ABBV) sells venetoclax under the Venclexta name.

Eli Lilly Reports Strong Phase 3 Results

The BRUIN CLL-322 trial results mark the fourth positive Phase 3 study for pirtobrutinib, indicating its potential for label expansion later this year.

The trial demonstrated that the addition of pirtobrutinib led to a statistically ...